The White House pulled Heidi Overton’s nomination to lead the Food and Drug Administration late on Tuesday, a day before the Senate committee was due to vote on whether to advance her.
Axios first reported the decision. A White House official then confirmed it to CNN and other outlets, saying Overton lacked the support on Capitol Hill to move forward.
The Senate Health, Education, Labor and Pensions Committee had been scheduled to vote on Wednesday. Republicans hold a one-vote majority on the 21-member panel, so a single defection would have sunk the nomination if every Democrat voted no, and no Democrats were expected to back her.

Overton, a preventive medicine doctor and deputy director of the White House Domestic Policy Council, was nominated in August to replace Marty Makary, who resigned as commissioner in May. Kyle Diamantas has led the agency as acting commissioner since then.
The nomination drew scrutiny for weeks. Committee chair Bill Cassidy said on Tuesday night that Overton was close to winning enough support, and wrote on X that the White House had “abandoned a viable confirmation path” for her. Other senators had raised questions about her experience and her stance on mifepristone, the abortion pill, which the FDA is due to finish reviewing in March.
The withdrawal leaves the FDA without a permanent leader well into next year, according to CNN. Outgoing Kansas Senator Roger Marshall, who lost his re-election bid this month, has expressed interest in the job, one person familiar with private discussions told Reuters. The White House has not said when it will name a new nominee.
Source: CNN